HCW Biologics Regains Full Rights to Two Commercial-Ready CAR-T Reagents for Free
HCWB has more than doubled off its 52-week low of $0.25 on light trading volume (0.2× avg).
Summary
HCW Biologics has regained full ex vivo rights to two commercial-ready reagents, HCW9206 and HCW9201, from Wugen Inc. at no cost, retaining the original license fee and 2.2 million Wugen shares. This move positions the company to enter the multi-billion-dollar CAR-T immunotherapy market, with recent data suggesting HCW9206 can reduce CAR-T production costs and improve therapeutic efficacy. This strategic asset acquisition is a significant positive development for HCW Biologics, which has recently faced a going concern warning, Nasdaq delisting notice, and a highly dilutive $5.6 million offering. The company plans to commercialize these reagents through new corporate partnerships.
At the time of this announcement, HCWB was trading at $2.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.6M. The 52-week trading range was $0.25 to $8.75. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.